Side effects of Sparsentan requiring immediate medical attention

During treatment with Sparsentan, regular monitoring is required. Follow-up should be conducted before treatment and monthly for the first 12 months, followed by evaluations every 3 months thereafter, including blood tests and urinalysis to assess efficacy and the risk of adverse reactions.

Side effects of Sparsentan requiring immediate medical attention

While Sparsentan exerts its therapeutic effects, it may also cause side effects. If severe adverse reactions occur, seek medical attention promptly.

Common side effects

During treatment with Sparsentan, patients may experience swelling of the face, arms, hands, lower legs, or feet; blurred vision; chills; confusion; orthostatic hypotension (dizziness or fainting when rising from a lying or sitting position); arrhythmia; nausea and vomiting; anxiety; numbness in the limbs (hands, feet, or lips); pale skin; sudden weight gain; excessive sweating; tingling in the extremities; difficulty breathing; unusual bleeding or bruising; persistent fatigue; abnormal weight fluctuations; weakness or heaviness in the lower limbs.

Less common side effects

During treatment with Sparsentan, patients may experience agitation-like movements; consciousness disorders (coma or drowsiness); reduced urine output; depression accompanied by hostility; persistent headache; increased nervous excitability; muscle twitching; and swelling of the face, ankles, or hands.

Side effects with unknown incidence

Dark urine; loss of appetite; severe stomach pain; yellowing of the eyes or skin. Although the incidence of these side effects is unknown, they may still occur during treatment with Sparsentan.

Side effects of Sparsentan for medical professionals

Cardiovascular

Very common (10% or more): Peripheral edema (14%), hypotension (14%).

Hematologic

(1) Very common (10% or more): Decreased hemoglobin (11%).

(2) Common (1%-10%): Anemia. A decrease in hemoglobin greater than 2 g/dL from baseline and below the lower limit of normal is more common with this drug; hemodilution may be a contributing factor. No treatment discontinuation due to anemia or hemoglobinemia has been reported.

Hepatotoxicity

Common (1%-10%): Elevated transaminases. Elevated transaminases occurred in 2.5% of patients and were reported as adverse events when greater than three times the upper limit of normal (3xULN). No cases of liver failure or bilirubin elevation (greater than 2xULN) have been observed with this drug.

Metabolic

(1) Very common (10% or more): Hyperkalemia (13%).

(2) Patients with advanced kidney disease, those concurrently taking medications that increase potassium, or those using potassium-containing salt substitutes are at higher risk for hyperkalemia.

Neurologic

Very common (10% or more): Dizziness (13%).

Nephrotoxicity

(1) Common (1%-10%): Acute kidney injury.

(2) Frequency not reported: Decreased estimated glomerular filtration rate. Patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, volume depletion, or those whose renal function may partially depend on the activity of the renin-angiotensin system may be at higher risk for acute kidney injury.